Pemigatinib is a targeted drug used for the targeted treatment of specific types of cancer. This article will explore in detail the price range of pemigatinib, its pharmacological mechanism of action, and its possible interactions with other drugs. The version of pemigatinib produced by Paraguay's Bockron Pharmaceutical Factory has a specification of 4.5mg*21 capsules, with a price of 391 US dollars per box.

 What is the Price of Pemigatinib?

The price of pemigatinib varies due to a variety of factors. In the domestic market, the price of the original research drug of pemigatinib is relatively high.

(1) Price Difference Between Original Research Drugs and Generic Drugs

Original research drugs refer to drugs produced by the company that initially developed the drug, and their prices are usually relatively high. Generic drugs, on the other hand, are drugs with the same active ingredients and therapeutic effects produced by other companies after the expiration of the patent protection period of the original research drug, and their prices are relatively low. At present, there are multiple versions of generic pemigatinib on the market, providing more options for patients.

(2) Specific Prices

Lucius (Laos) version: 4.5mg*14 tablets, priced at approximately 124 US dollars per box.

Pemigatinib (Hong Kong, China) version: 13.5mg*14 tablets, priced at approximately 9,536 US dollars per box.

Bockron Pharmaceutical Factory (Paraguay) version: 4.5mg*21 capsules, priced at approximately 391 US dollars per box.

The above prices are for reference only. Patients can purchase selectively according to their own needs.

 What is the Pharmacological Action of Pemigatinib?

Pemigatinib is a tyrosine kinase inhibitor, which exerts its pharmacological effects mainly by inhibiting the activity of fibroblast growth factor receptors (FGFR).

(1) Inhibiting the FGFR Signaling Pathway

FGFR is a type of transmembrane receptor tyrosine kinase that is involved in physiological processes such as cell proliferation, differentiation, migration, and angiogenesis. In cancer cells, the abnormal activation of FGFR leads to excessive cell proliferation and malignant transformation. Pemigatinib specifically inhibits the activity of FGFR, blocks the transmission of its downstream signaling pathways, and thereby inhibits the growth and spread of cancer cells.

(2) Improving Therapeutic Efficacy and Safety

Compared with traditional chemotherapeutic drugs, pemigatinib has higher targeting and lower toxic and side effects. It only acts on specific cancer cells and does not cause significant damage to normal cells. While improving the therapeutic effect, pemigatinib can also reduce the adverse reactions and side effects in patients.

 Drug Interactions of Pemigatinib

Pemigatinib may interact with other drugs, and such interactions may affect the metabolism, efficacy, and safety of the drug.

(1) Interactions with CYP3A4 Inhibitors and Inducers

CYP3A4 is one of the important drug-metabolizing enzymes in the human body and is involved in the metabolism of a variety of drugs. When pemigatinib is used in combination with CYP3A4 inhibitors, it may reduce the metabolic rate of pemigatinib, increasing its blood concentration and efficacy. However, when used in combination with CYP3A4 inducers, it may accelerate the metabolism of pemigatinib, reducing its blood concentration and efficacy.

(2) Potential Interactions with Other Drugs

In addition to CYP3A4 inhibitors and inducers, pemigatinib may also interact with other drugs. For example, when used in combination with certain anti-infective drugs, it may affect the efficacy and safety of each other. When using pemigatinib, patients should inform their doctors of all drugs they are currently using, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements.

When using pemigatinib, patients should follow the doctor's instructions, take the drug on time and in the correct dosage, and pay close attention to their own physical conditions.